Quotient Clinical Completes Enabled FIH Program

May 15, 2015
Applied Clinical Trials Editorial Staff

Applied Clinical Trials

Quotient Clinical has announced results from an Enabled-First-in-Human (Enabled-FIH) program conducted for the Janssen WAVE Early Development unit.

Quotient Clinical has announced results from an Enabled-First-in-Human (Enabled-FIH) program conducted for the Janssen WAVE Early Development unit. The integrated pharmaceutical development and first-in-human clinical program was designed to develop an optimal oral formulation, in parallel with the assessment of single and multiple dose safety, pharmacokinetics and pharmacodynamics of a highly selective small molecule c-Met tyrosine kinase inhibitor. The clinical phase, which was conducted under a single, adaptive protocol, was completed in only six months. 

 

Read the full release here.